Paeds Cases · allergy-and-immunology
Food allergy OSCE — acute reaction drill and early-introduction prevention counselling
Observed structured encounter testing emergency anaphylaxis management, the written-action-plan ladder, and counselling a high-risk infant's family on early allergen introduction.
On this page & tools
Target exams
Station objectives
- Manage a food-induced anaphylaxis drill with adrenaline-first reasoning. [14]
- Build the written-action-plan and autoinjector ladder for discharge. [6]
- Counsel a high-risk infant's family on early allergen introduction, using the LEAP evidence. [1] [4]
Candidate brief
You are the paediatric doctor in a mixed acute and allergy clinic. Station A is 8 minutes (acute reaction). Station B is 8 minutes (preventive counselling). Examiners score safety prioritisation, evidence use, and partnership with families. [6] [14]
Station A — Anaphylaxis drill
Setup: A six-year-old with known peanut allergy and mild asthma develops lip swelling, urticaria, wheeze and drowsiness within minutes of a biscuit at a party. A carer has a 0.15 mg adrenaline autoinjector. [14]
Expected actions:
- Declare anaphylaxis and call for help. [14]
- Give IM adrenaline into the anterolateral thigh first — not an antihistamine. [14]
- Lie flat with legs elevated if shocked, high-flow oxygen, IV fluids for shock, bronchodilator adjunctive. [14]
- Repeat adrenaline at five minutes if no response. [14]
- Plan observation for biphasic reaction (at least six hours); admit because of asthma and severity. [14] [6]
- Leave the family with a written action plan, two weight-banded autoinjectors, and a school plan. [6]
Station B — Prevention counselling
Setup: A parent of a four-month-old with severe early-onset eczema has read online that allergenic foods should be delayed to prevent allergy, and asks what to do. [1] [4]
Expected actions:
- Correct the misconception: delayed introduction increases, not reduces, allergy risk. [1] [13]
- Explain the LEAP evidence in plain language: early sustained peanut cut peanut allergy by roughly 80% relative risk. [1]
- Risk-stratify this high-risk infant (severe eczema) with a skin-prick test before introducing peanut; introduce early if low or negative, specialist-led if positive. [1] [4]
- Advise introducing common allergens around four to six months and keeping them in the diet (sustained intake). [4] [13]
- Confirm: no maternal diet restriction in pregnancy or lactation; continue breastfeeding. [13]
Marking anchors
Clear pass: adrenaline-first anaphylaxis with correct dose and repeat logic; biphasic-aware disposition; full action-plan ladder; correct early-introduction counselling with LEAP evidence and risk-stratified peanut. [1] [14] Borderline: right drug but delayed by waiting for antihistamine or IV access; or counsels early introduction but omits skin-prick risk-stratification in the severe-eczema infant. [4] [14] Fail: gives antihistamine first for a wheezing hypotensive child; or advises delaying allergens; or restricts the maternal diet. [1] [14]
Debrief pearls
- Adrenaline first, every time — antihistamines treat itch, not airway or circulation. [14]
- The question for the high-risk infant is not whether to introduce, but how early and whether to test first. [1] [4]
- Tolerance needs sustained intake — introducing then abandoning a food leaves the door ajar. [6]
References
- [1]Du Toit G Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med, 2015.PMID 25705822
- [4]Togias A Addendum guidelines for the prevention of peanut allergy in the United States: Report of the NIAID-sponsored expert panel. J Allergy Clin Immunol, 2017.PMID 28065278
- [6]Sicherer SH Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management. J Allergy Clin Immunol, 2018.PMID 29157945
- [13]Halken S EAACI guideline: Preventing the development of food allergy in infants and young children (2020 update). Pediatr Allergy Immunol, 2021.PMID 33710678
- [14]Simons FE World Allergy Organization Anaphylaxis Guidelines: 2013 update of the evidence base. Int Arch Allergy Immunol, 2013.PMID 24008815